Nicolas Rouyrre

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

James C. Yao, Nicola Fazio, Simron Singh et al. · The Lancet · 2015 · 1.3K citations

Medicine, Oncology, Surgery +12

Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors

K. Mross, Annette Frost, Simone Steinbild et al. · Journal of Clinical Oncology · 2008 · 158 citations · Full text

Pharmacy, Oncology, Pharmacology +14

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study

Marianne Pavel, Éric Baudin, Kjell E. Öberg et al. · Annals of Oncology · 2017 · 120 citations · Full text

Medicine, Oncology, Pharmacology +17

Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study

Dejan Juric, Jordi Rodón, Ana M. González-Angulo et al. · Cancer Research · 2012 · 62 citations

Medicine, Oncology, Pharmacology +16

Immunogenicity and safety of low-dose intradermal rabies vaccination given during an Expanded Programme on Immunization session in Viet Nam: results of a comparative randomized trial

Jean Lang, Duong Quynh Hoa, Nguyen V. Gioi et al. · Transactions of the Royal Society of Tropical Medicine and Hygiene · 1999 · 58 citations

Medicine, Immunology, Pediatrics +17